186 related articles for article (PubMed ID: 9704709)
21. Enhanced levels and enhanced clonogenic capacity of blood progenitor cells following administration of stem cell factor plus granulocyte colony-stimulating factor to humans.
Begley CG; Basser R; Mansfield R; Thomson B; Parker WR; Layton J; To B; Cebon J; Sheridan WP; Fox RM; Green MD
Blood; 1997 Nov; 90(9):3378-89. PubMed ID: 9345020
[TBL] [Abstract][Full Text] [Related]
22. Repetitive cycles of cyclophosphamide, thiotepa, and carboplatin intensification with peripheral-blood progenitor cells and filgrastim in advanced breast cancer patients.
Shapiro CL; Ayash L; Webb IJ; Gelman R; Keating J; Williams L; Demetri G; Clark P; Elias A; Duggan D; Hayes D; Hurd D; Henderson IC
J Clin Oncol; 1997 Feb; 15(2):674-83. PubMed ID: 9053493
[TBL] [Abstract][Full Text] [Related]
23. Stem cell factor and high-dose twice daily filgrastim is an effective strategy for peripheral blood stem cell mobilization in patients with indolent lymphoproliferative disorders previously treated with fludarabine: results of a Phase II study with an historical comparator.
Herbert KE; Morgan S; Prince HM; Westerman DA; Wolf MM; Carney DA; Yuen K; di Iulio J; Seymour JF
Leukemia; 2009 Feb; 23(2):305-12. PubMed ID: 18987661
[TBL] [Abstract][Full Text] [Related]
24. Stem cell mobilization with G-CSF alone in breast cancer patients: higher progenitor cell yield by delivering divided doses (2 x 5 microg/kg) compared to a single dose (1 x 10 microg/kg).
Kröger N; Zeller W; Hassan HT; Krüger W; Gutensohn K; Löliger C; Zander AR
Bone Marrow Transplant; 1999 Jan; 23(2):125-9. PubMed ID: 10197796
[TBL] [Abstract][Full Text] [Related]
25. A randomized comparison of once versus twice daily recombinant human granulocyte colony-stimulating factor (filgrastim) for stem cell mobilization in healthy donors for allogeneic transplantation.
Kröger N; Renges H; Krüger W; Gutensohn K; Löliger C; Carrero I; Cortes L; Zander AR
Br J Haematol; 2000 Dec; 111(3):761-5. PubMed ID: 11122135
[TBL] [Abstract][Full Text] [Related]
26. Combination of stem cell factor and granulocyte colony-stimulating factor mobilizes the highest number of primitive haemopoietic progenitors as shown by pre-colony-forming unit (pre-CFU) assay.
Horsfall MJ; Hui CH; To LB; Begley CG; Basser RL; Simmons PJ
Br J Haematol; 2000 Jun; 109(4):751-8. PubMed ID: 10929025
[TBL] [Abstract][Full Text] [Related]
27. Correlation between granulocyte/macrophage-colony-forming units and CD34+ cells in apheresis products from patients treated with different chemotherapy regimens and granulocyte-colony-stimulating factor to mobilize peripheral blood progenitor cells.
Vogel W; Kunert C; Blumenstengel K; Fricke HJ; Kath R; Sayer HG; Höffken K
J Cancer Res Clin Oncol; 1998; 124(6):341-5. PubMed ID: 9692843
[TBL] [Abstract][Full Text] [Related]
28. Mobilization of peripheral blood stem cells in high-risk breast cancer patients using G-CSF after standard dose docetaxel.
Fleming DR; Goldsmith J; Goldsmith GH; Stevens DA; Herzig RH
J Hematother Stem Cell Res; 2000 Dec; 9(6):855-60. PubMed ID: 11177597
[TBL] [Abstract][Full Text] [Related]
29. A randomized phase 3 study of peripheral blood progenitor cell mobilization with stem cell factor and filgrastim in high-risk breast cancer patients.
Shpall EJ; Wheeler CA; Turner SA; Yanovich S; Brown RA; Pecora AL; Shea TC; Mangan KF; Williams SF; LeMaistre CF; Long GD; Jones R; Davis MW; Murphy-Filkins R; Parker WR; Glaspy JA
Blood; 1999 Apr; 93(8):2491-501. PubMed ID: 10194427
[TBL] [Abstract][Full Text] [Related]
30. Comparative effects of three cytokine regimens after high-dose cyclophosphamide: granulocyte colony-stimulating factor, granulocyte-macrophage colony-stimulating factor (GM-CSF), and sequential interleukin-3 and GM-CSF.
Ballestrero A; Ferrando F; Garuti A; Basta P; Gonella R; Stura P; Mela GS; Sessarego M; Gobbi M; Patrone F
J Clin Oncol; 1999 Apr; 17(4):1296. PubMed ID: 10561192
[TBL] [Abstract][Full Text] [Related]
31. Mobilization of peripheral blood progenitor cells (PBPC) through a combination of chemotherapy and G-CSF in breast cancer patients and a possibility of unprocessed whole blood collection.
Vanásek J; Filip S; Medková V; Bláha M; Mericka P; Volenec K
Bone Marrow Transplant; 1998 Jan; 21(2):123-6. PubMed ID: 9489627
[TBL] [Abstract][Full Text] [Related]
32. Ancestim (recombinant human stem cell factor, SCF) in association with filgrastim does not enhance chemotherapy and/or growth factor-induced peripheral blood progenitor cell (PBPC) mobilization in patients with a prior insufficient PBPC collection.
da Silva MG; Pimentel P; Carvalhais A; Barbosa I; Machado A; Campilho F; Sousa SR; Miranda N; da Costa FL; Campos A; Vaz CP; Antas J; Passos-Coelho JL
Bone Marrow Transplant; 2004 Oct; 34(8):683-91. PubMed ID: 15322567
[TBL] [Abstract][Full Text] [Related]
33. Beyond CD34+ cell dose: impact of method of peripheral blood hematopoietic stem cell mobilization (granulocyte-colony-stimulating factor [G-CSF], G-CSF plus plerixafor, or cyclophosphamide G-CSF/granulocyte-macrophage [GM]-CSF) on number of colony-forming unit-GM, engraftment, and Day +100 hematopoietic graft function.
Alexander ET; Towery JA; Miller AN; Kramer C; Hogan KR; Squires JE; Stuart RK; Costa LJ
Transfusion; 2011 Sep; 51(9):1995-2000. PubMed ID: 21392017
[TBL] [Abstract][Full Text] [Related]
34. Successful mobilization of peripheral blood HPCs with G-CSF alone in patients failing to achieve sufficient numbers of CD34+ cells and/or CFU-GM with chemotherapy and G-CSF.
Fraipont V; Sautois B; Baudoux E; Pereira M; Fassotte MF; Hermanne JP; Jérusalem G; Longrée L; Schaaf-Lafontaine N; Fillet G; Beguin Y
Transfusion; 2000 Mar; 40(3):339-47. PubMed ID: 10738037
[TBL] [Abstract][Full Text] [Related]
35. Effects of prior therapy on the in vitro proliferative potential of stem cell factor plus filgrastim-mobilized CD34-positive progenitor cells.
Shapiro F; Yao TJ; Moskowitz C; Reich L; Wuest DL; Heimfeld S; McNiece IK; Gabrilove J; Nimer S; Moore MA
Clin Cancer Res; 1997 Sep; 3(9):1571-8. PubMed ID: 9815845
[TBL] [Abstract][Full Text] [Related]
36. Peripheral blood stem cell mobilization by chemotherapy with and without recombinant human granulocyte colony-stimulating factor.
Schwartzberg LS; Birch R; Hazelton B; Tauer KW; Lee P; Altemose R; George C; Blanco R; Wittlin F; Cohen J
J Hematother; 1992; 1(4):317-27. PubMed ID: 1285381
[TBL] [Abstract][Full Text] [Related]
37. A randomized phase 2 study of PBPC mobilization by stem cell factor and filgrastim in heavily pretreated patients with Hodgkin's disease or non-Hodgkin's lymphoma.
Stiff P; Gingrich R; Luger S; Wyres MR; Brown RA; LeMaistre CF; Perry J; Schenkein DP; List A; Mason JR; Bensinger W; Wheeler C; Freter C; Parker WRL ; Emmanouilides C
Bone Marrow Transplant; 2000 Sep; 26(5):471-81. PubMed ID: 11019835
[TBL] [Abstract][Full Text] [Related]
38. Analysis of stem cell apheresis products using intermediate-dose filgrastim plus large volume apheresis for allogeneic transplantation.
Engelhardt M; Bertz H; Wäsch R; Finke J
Ann Hematol; 2001 Apr; 80(4):201-8. PubMed ID: 11401085
[TBL] [Abstract][Full Text] [Related]
39. Sequential analysis of CD34+ and CD34- cell subsets in peripheral blood and leukapheresis products from breast cancer patients mobilized with SCF plus G-CSF and cyclophosphamide.
Menéndez P; Prósper F; Bueno C; Arbona C; San Miguel JF; García-Conde J; Solá C; Hornedo J; Cortés-Funes H; Orfao A
Leukemia; 2001 Mar; 15(3):430-9. PubMed ID: 11237067
[TBL] [Abstract][Full Text] [Related]
40. Mobilization strategies for the collection of peripheral blood progenitor cells: Results from a pilot study of delayed addition G-CSF following chemotherapy and review of the literature.
Jacoub JF; Suryadevara U; Pereyra V; Colón D; Fontelonga A; Mackintosh FR; Hall SW; Ascensão JL
Exp Hematol; 2006 Nov; 34(11):1443-50. PubMed ID: 17046563
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]